Success Stories: With Premium Processing and the Efforts of Our Teammates, A Professor in the Field of Pharmaceutical Biotechnology Secures EB1-A Approval in Just 1 Month, and 4 Days.
Client’s Testimonial:
“I would like to thank the law firm for all this help. Your service is highly appreciated”
On September 12th, 2023, we received another EB-1A (Alien of Extraordinary Ability) approval for a Professor in the field of Pharmaceutical Biotechnology (Approval Notice).
General Field: Pharmaceutical Biotechnology
Position at the Time of Case Filing: Professor
Approval Notice Date: September 12th, 2023
Processing Time: 1 month, 4 days (Premium Processing Requested)
Case Summary:
Having accumulated two recommendation letters, our client, a professor, working in the field of pharmaceutical biotechnology after completing his Ph.D. degree in biochemistry, approached us to file his alien of extraordinary ability (EB1-A) petition.
Since a petition for the first preference category of individuals with extraordinary ability, (“EB1- A”), unlike the employment-based immigration visa under the second preference (“EB-2”), at least requires:
- Evidence of original contributions, usually through publication, is of major significance in the foreign national’s science, academic, artistic, or athletic field.
- No specific job offer/labor certification is required for a foreign person as long as he/she is entering the United States to continue work in the field where he/she has an extraordinary ability; therefore, self-petition is allowed.
- Performance in a significant role for organizations or establishments that have a distinguished reputation.
- Receipt of a higher salary or remuneration than is usual in the field.
- Other comparable evidence if the above evidence does not readily apply to the foreign national’s occupation.
Therefore, we assimilated the following essentials from his academic and professional records in his petition packet to make a convincing case in his favor:
- His research addresses some of our nation’s and the world’s most pressing issues, including the need for the development of effective antibiotics, and antiviral agents particularly in developing COVID-19 treatments and addressing drug resistance.
- He is particularly well-known for his contributions to identifying secondary metabolites from natural products for COVID-19 treatments.
- His research has resulted over 60 peer-reviewed scientific articles, being cited 1,396 times from several countries according to Google Scholar.
- He has conducted 100 reviews to date.
- His study has also received funding from many government/ private organizations which supports projects that provide knowledge and technology for national socioeconomic development.
After evaluating our client’s research, we deduced that it stands out in the field due to its applications in identifying drug candidates for the treatment of COVID-19 and advancing further research in pharmaceutical biotechnology. His work is dedicated to advances in pharmaceutical biotechnology, which are matters of critical national importance. Researchers who are highly skilled in this area are thus crucial to the United States.
Finally, he achieved his EB1-A (Alien of Extraordinary Ability) approval in 1 month and 4 days only (thanks to premium processing).
We are delighted to be part of his victorious journey and would like to send him best wishes for his future endeavors.

